As of May 2018, Orlando leads the program strategy for the recently announced Chimeric Antigen Receptor T-Cells therapeutic area. This includes digital strategies, supply chain network design, and supply chain capability development for this therapy platform, currently targeted as a last line of defense for multiple myeloma.

In addition to existing responsibilities for e-Business, assigned the leadership role of managing the complete information technology portfolio for all functional groups in the company, including global (i.e. manufacturing, supply-chain, quality systems) and regional (i.e. Marketing and Sales) organizations.
Portfolio management activities includes drastically changing the investment-to-base business ratio of a $35MM/year budget, IM expense-to-sales ratio, project prioritization,